/
Oncology
Small Cell Lung Cancer ( SCLC )
16
Pipeline Programs↗
12
Active Trials↗
14
Companies Involved↗
Small Cell Lung Cancer ( SCLC ) is an emerging landscape with 16 programs across 14 companies. The most active players are Phanes Therapeutics, Pfizer. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical8
Phase 31
Approved
No programs
Analysis
Modality Breakdown
12programs
Small molecule758%
Monoclonal antibody433%
Antibody–drug conjugate18%
Modality classified for 88% of 16 pipeline programs.
Analysis
Trial Status
13
clinical trials
Recruiting9 · 69%
Not yet recruiting2 · 15%
Active, not recruiting1 · 8%
Withdrawn1 · 8%
Clinical Trials
Trial Activity
13 trials
Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Recruiting·—·Phase 2·NCT07339059·35 enrolled
An Exploratory Phase II Study of Bemotuzumab Combined With Chemotherapy and Anlotinib as Induction Therapy, Followed by Bemotuzumab, Anlotinib, and Consolidative Thoracic Radiotherapy in Patients With Extensive-Stage Small Cell Lung Cancer
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07358676·25 enrolled
A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for Elderly Patients With Small-cell Lung Cancer or Those Who Are Intolerant to Intensive Chemotherapy
Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT07728955·64 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)